Currently, there are 136.96M common shares owned by the public and among those 136.19M shares have been available to trade.
The company’s stock has a 5-day price change of -49.82% and -70.45% over the past three months. BLRX shares are trading -35.79% year to date (YTD), with the 12-month market performance down to -90.90% lower. It has a 12-month low price of $0.14 and touched a high of $1.52 over the same period. BLRX has an average intraday trading volume of 4.28 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -32.56%, -54.71%, and -75.75% respectively.
Institutional ownership of Bioline Rx Ltd ADR (NASDAQ: BLRX) shares accounts for 2.44% of the company’s 136.96M shares outstanding.
It has a market capitalization of $18.82M and a beta (3y monthly) value of 1.50. The earnings-per-share (ttm) stands at -$0.27. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.43% over the week and 14.94% over the month.
Earnings per share for the fiscal year are expected to increase by 91.44%, and -8.69% over the next financial year.
Looking at the support for the BLRX, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on May 18, 2017, with the firm’s price target at $1-$3. Rodman & Renshaw coverage for the Bioline Rx Ltd ADR (BLRX) stock in a research note released on February 13, 2017 offered a Buy rating with a price target of $3. Maxim Group was of a view on August 12, 2016 that the stock is Hold, while Maxim Group gave the stock Buy rating on August 17, 2015, issuing a price target of $8- $4. ROTH Capital on their part issued Buy rating on July 27, 2015.
